⁹⁰Y/¹⁷⁷Lu-DOTATOC: From Preclinical Studies to Application in Humans

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Therapy

Background:

• Neuroendocrine tumors (NETs) often present as inoperable or metastatic.
• Standard therapies for NETs have limitations in efficacy and side effect profiles.
• Peptide Receptor Radionuclide Therapy (PRRT) has emerged as a significant treatment modality.

Purpose of the Study:

• To review the characteristics and performance of [90Y]Y-DOTATOC and [177Lu]Lu-DOTATOC.
• To summarize the key literature findings over 25 years regarding these radiopharmaceuticals.
• To trace the progression of these therapies from preclinical research to clinical application.

Main Methods:

• Literature review covering 25 years of research on PRRT for NETs.
• Analysis of studies focusing on [90Y]Y-DOTATOC and [177Lu]DOTATOC.
• Evaluation of progression-free survival (PFS) and overall survival (OS) data.

Main Results:

• PRRT demonstrates favorable progression-free survival (PFS) and overall survival (OS) for NET patients.
• [90Y]Y-DOTATOC and [177Lu]Lu-DOTATOC are the most utilized radiopharmaceuticals in NET PRRT.
• Significant results from preclinical and clinical studies support the efficacy of these agents.

Conclusions:

• PRRT using [90Y]Y-DOTATOC and [177Lu]Lu-DOTATOC is an effective treatment for inoperable or metastatic NETs.
• These radiopharmaceuticals have successfully transitioned from research to clinical practice.
• Continued research and application of PRRT are crucial for improving NET patient outcomes.